Abstract
Drug abuse is currently a large economic and societal burden in countries around the globe. Many drugs of abuse currently lack adequate therapies aimed at treating both the addiction and negative complications often associated with their use. Sigma-1 receptors were discovered over 30 years ago and have recently become targets for the development of pharmacotherapies aimed at treating substance abuse and addiction. In vivo preclinical studies have revealed that sigma receptor ligands are able to ameliorate select behavioral effects of many drugs of abuse including cocaine, methamphetamine, ethanol and nicotine. In addition, recent studies have begun to elucidate the mechanisms by which sigma-1 receptors modulate the effects of these drugs on neurotransmission, gene regulation and neuroplasticity. Overall, these recent findings suggest that compounds targeting sigma-1 receptors may represent a potential new class of therapeutics aimed at treating drug abuse. Future studies involving clinical populations will be critical for validating the therapeutic potential of sigma-1 receptor ligands for the treatment of substance abuse.
Keywords: Sigma receptor, cocaine, methamphetamine, nicotine, ethanol, drug abuse, addiction, opioid, neurotransmission, neuroplasticity
Current Pharmaceutical Design
Title: Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Volume: 18 Issue: 7
Author(s): Matthew J. Robson, Bahar Noorbakhsh, Michael J. Seminerio and Rae R. Matsumoto
Affiliation:
Keywords: Sigma receptor, cocaine, methamphetamine, nicotine, ethanol, drug abuse, addiction, opioid, neurotransmission, neuroplasticity
Abstract: Drug abuse is currently a large economic and societal burden in countries around the globe. Many drugs of abuse currently lack adequate therapies aimed at treating both the addiction and negative complications often associated with their use. Sigma-1 receptors were discovered over 30 years ago and have recently become targets for the development of pharmacotherapies aimed at treating substance abuse and addiction. In vivo preclinical studies have revealed that sigma receptor ligands are able to ameliorate select behavioral effects of many drugs of abuse including cocaine, methamphetamine, ethanol and nicotine. In addition, recent studies have begun to elucidate the mechanisms by which sigma-1 receptors modulate the effects of these drugs on neurotransmission, gene regulation and neuroplasticity. Overall, these recent findings suggest that compounds targeting sigma-1 receptors may represent a potential new class of therapeutics aimed at treating drug abuse. Future studies involving clinical populations will be critical for validating the therapeutic potential of sigma-1 receptor ligands for the treatment of substance abuse.
Export Options
About this article
Cite this article as:
J. Robson Matthew, Noorbakhsh Bahar, J. Seminerio Michael and R. Matsumoto Rae, Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436601
DOI https://dx.doi.org/10.2174/138161212799436601 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardioprotective Role of <i>Theobroma cacao</i> against Isoproterenol-Induced
Acute Myocardial Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Current Pharmaceutical Design Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
Current Medicinal Chemistry Hypersensitivity to Lamotrigine and Nonaromatic Anticonvulsant Drugs: A Review
Current Pharmaceutical Design Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Herpetic (Non-Cytomegalovirus) Retinal Infections in Patients with the Acquired Immunodeficiency Syndrome
Current HIV Research Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety Biological Nitration of Arachidonic Acid
Current Vascular Pharmacology Connexins in Renal Endothelial Function and Dysfunction
Cardiovascular & Hematological Disorders-Drug Targets Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology New Insights into the Pathogenesis of and Long-Term Risks in Children with Henoch-Schonlein Purpura Nephritis
Current Pediatric Reviews Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design Steroid Induced Bilateral Avascular Necrosis of Head of Femur in an Adult Male Patient - A Case Report
Current Drug Safety Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design